Treatment
Patients with ≥ 50% PD-L1 expression were assigned for neoadjuvant nivolumab monotherapy (360 mg, on day 1) intravenously (N) for three cycles (each 21-day cycle) (arm A1) at first. After prospectively completing arm A1 enrollment, the following patients with ≥ 50% PD-L1 expression were enrolled in arm A2 with nivolumab (360 mg, on day 1) plus nab-paclitaxel (135 mg/mSurgery was planned within 42 days following completing the neoadjuvant treatment, after which the patients received 12-month adjuvant intravenous nivolumab monotherapy (360 mg once every 3 weeks) (Supplementary Figure 